3D Cell Screening Service


oncotest SBH-Sciences reinnervate-logo-footer

 

Reinnervate is pleased to announce a low cost, introductory service for screening novel anti-cancer therapies on 3D tumour cells grown in Alvetex Scaffold 96 well plates. This service is offered in conjunction with our Oncology CRO partners Oncotest (Freiburg, Germany) and SBH Sciences (MA, USA). The service uses proprietary patient-derived tumour xenograft cell lines as well as a panel of over 200 standard human tumor cell lines.

 

Brief outline of the service offered:

  • You pick 2 tumour cell lines from the introductory service panel.
  • You provide 2 test compounds or specify 2 commercially available drugs to be used.
  • CRO includes 1 positive control cell line and 1 positive control compound.
  • All 3 compounds are tested on the specified 3D tumour cells cultured Alvetex® 96 plates.
  • A dose response experiment with 10 concentrations in duplicates will be performed using the Promega Cell Titer-Glo® assay.
  • You get a comprehensive data report with IC50 values and a follow-up telephone conference.
  • CRO carries out a 2D vs 3D cell culture comparison (depending on service chosen).
  • Prices from $1,499 to $2,499 depending on service chosen (excluding taxes and shipping charges).

 

Applications:

  • Pre-clinical evaluation of anti-cancer compounds in a 3D cell culture model.
  • Evaluation of compound potency in comparison to standard of care drugs in 3D culture.
  • Identification of tumor models for subsequent in vivo studies using the corresponding patient derived xenograft.

 

graph1
Response to 5-FU treatment by HCT116 cells in 2D and 3D culture (4 day culture, 72hr drug exposure).

 

Choose two of the following Oncotest cell lines:

 

Cell Lines Established From Patient-Derived Xenografts at Oncotest

 

Histotype Name Histopathology
1 Bladder BXF 1218L Urothelca, pd
2 Bladder BXF 1352L Urothelca, pd
3 Colon CXF 269L Rectum carcinoma, pd
4 Gastric GXF 251L adeno ca, pd
5 Lung LXFA 289L adeno ca, pd
6 Lung LXFA 526L adeno ca, pd
7 Lung LXFA 629L adeno ca, pd
8 Lung LXFL 1121L large cell, pd
9 Lung LXFL 529L large cell, pd
10 Mammary MEXF 401NL adeno ca, pd
11 Melanoma MEXF 1341L amelanotic melanoma
12 Melanoma MEXF 276L amelanotic melanoma
13 Melanoma MEXF 462NL amelanotic melanoma
14 Ovarian OVXF 899L papill serous adeno, wd
15 Pancreas PAXF 1657L adeno ca, md
16 Pancreas PAXF 546L adenoaquamous, wd
17 Pleuramesoth. PXF 1752L pleuramesothelioma
18 Pleuramesoth. PXF 698L pleuramesothelioma
19 Renal RXF 1781L hypernephroma, pd
20 Renal RXF 393NL hypernephroma, pd
21 Renal RXF 486L hypernephroma, pd
22 Uterus UXF 1138L endometrium carcino sarcoma, pd

ca = carcinoma; pd = poorly differentiated; wd = well differentiated; md = moderately differentiated.

 

Cell Lines From Commercial Repositories

Histotype Name Histopathology
1 Bladder T24 Urothel ca
2 Colon HCT116 Colon ca, pd
3 Colon HT29 Colon adeno ca, pd
4 Colon RKO Epithelial colon ca, pd
5 Gastric MKN45 Adeno ca, pd
6 Head & neck CAL27 Squamous cell ca, tongue
7 Lung H460 Large cell, pd
8 Mammary MCF7 Mamma ca, pd
9 Mammary MDA-MB-231 Mamma ca, pd
10 Ovarian OVCAR3 Adeno ca
11 Prostate 22RV1 Prostate ca, pd
12 Prostate DU145 Prostate ca, pd
13 Prostate LNCAP Prostate ca, pd
14 Prostate PC3M Prostate ca, pd
15 Sarcoma SAOS2 Osteocarcoma
16 Sarcoma TE671 Rhabdomyosarcoma

ca = carcinoma; pd = poorly differentiated; wd = well differentiated; md = moderately differentiated.

 

Choose up to two of the following SBH Sciences cell lines
(partial list – over 200 cell lines available)

For the full list please e-mail rnir@sbhsciences.com


Organ

Cell
Line Name

Disease
BILE DUCT TFK-1 bile
duct carcinoma
HuCCT-1 bile
duct carcinoma
BONE U2OS Osteosarcoma
HT-1080 Fibrosarcoma
BRAIN HTB-14
= U-87 MG
Astrocytoma/Glioblastoma
LN-18 Glioblastoma
U-118 Astrocytoma/Glioblastoma
U-251MG Glioblastoma
T98G Glioblastoma
Multiforme
BREAST AU-565 Breast
Adenocarcinoma
MCF-7 Breast
Adenocarcinoma
MDA-MB-231 Breast
Adenocarcinoma
Sk-Br-3 Breast
Adenocarcinoma
MDA-MB-468 Breast
Adenocarcinoma
CERVIX Hela Cervical
Adenocarcinoma
MS751 epidermoid
carcinoma
COLON Colo-205 Colorectal
Adenocarcinoma (Dukes’ Type D)
HT-29
(HTB-38)
Colorectal
Adenocarcinoma
HCT-116 Colon
Carcinoma
HCT-15 Colorectal
Adenocarcinoma (Dukes’ Type C)
LoVo Colorectal
Adenocarcinoma (Dukes’ Type C)
EYE ARPE-19 Normal
KIDNEY HK-2 Proximal
Tubule Epithelial Cells (HPV-16)
LIVER Hep-3B Hepatocellular
Carcinoma
HEP-G2 Liver
Cancer
MHCC-97H hepatocellular
carcinoma
LUNG NCI-H1650
(H1650)
adenocarcinoma;
bronchoalveolar carcinoma
MRC-5 Normal
NCI-H28
(H-28)
Mesothelioma
NCI-H1299 carcinoma;
non-small cell lung cancer
A-549 Lung
Carcinoma
LEUKEMIA,
LYMPHOMA, MULTIPLE MYELOMA
MO7e Acute
Megakaryocytic Leukemia
THP-1 Acute
Monocytic Leukemia
AML-5 Acute
Myeloblastic Leukemia
MM.1S Immunoglobulin
A Lambda Myeloma
Z-138 mantle
cell lymphoma
OVARY Caov-3
(HTB-75)
Ovarian
Adenocarcinoma
SKOV-3 adenocarcinoma
OVCAR
8
Ovarian
Cancer
PANCREAS PANC-1 epithelioid
carcinoma
CAPAN-1 adenocarcinoma
PACA-2 Pancreatic
Carcinoma
RENAL
SARCOMA
FUUR
PROSTATE PC-3 Prostate
Adenocarcinoma
LnCAP Prostate
Carcinoma
DU-145 Prostate
Carcinoma
SKIN SK-MEL-2 Malignant
Melanoma
STOMACH SNU-5 Gastric
Carcinoma

Request a Quote

For more information or for a quote please contact us via our contact form.

In the Details box on the contact form, please mention the cell types that interest you.

We aim to respond to your request within 3 working days. We do not pass on your information to anyone else.